Thyssenkrupp: A Hydrogen Subsidy Locked In, a Supply Tender Still Open, and Two Signals Investors Shouldn't Conflate
Published on 11/05/2026 at 03:21 | Editorial boerse-global.de
Thyssenkrupp shareholders have two fresh data points to work through this week, and neither of them settles the question that really matters. On one side sits a funding amendment for the tkH2Steel hydrogen project that became legally binding roughly a week ago. On the other, Morgan Stanley has disclosed a stake that now reaches 7.96% of the company. The stock has been moving — up 2.7% in one session and 2.5% in another — but no concrete company announcement explains the advance, and investors would be wise to keep the price action separate from any operational verdict.
What the Amendment Does — and Doesn't — Deliver
The change notice for tkH2Steel, now bestandskräftig, gives Thyssenkrupp Steel planning certainty under altered economic conditions, according to the company. That closes out one funding question. It does not answer whether the planned hydrogen ramp-up can actually be delivered at a viable cost, and that distinction is the whole ballgame for anyone trying to value the equity.
Thyssenkrupp Steel is meanwhile steering the ramp-up more firmly toward availability and economic viability, and it is preparing a fresh hydrogen tender. The tender, not the legal paperwork, is the real test. Getting hydrogen is one thing; getting it on terms that make its use worthwhile is another. A tender in preparation is not a procurement result — it should be neither equated with secured supply nor with fixed commercial terms. Reading the preparation as an operational breakthrough gets ahead of an announced step; dismissing the newly won planning certainty as meaningless is just as short-sighted.
The Bull Case Rests on Terms, Not Paperwork
The optimistic reading hinges on where the funding framework and the procurement side meet. If the new tender produces an available and economically workable hydrogen supply, Thyssenkrupp could put its secured funding base to use for the next stage of the ramp-up. The gain would go beyond ticking off another procedural box: the project's commercial feasibility would come into sharper focus, and shareholders could judge progress by procurement terms rather than by the basic safeguarding of the venture.
In that scenario, the sharper focus on availability and cost reads as discipline. A ramp-up that respects those constraints deserves a different assessment from one pursued regardless of procurement costs. That remains a conditional view — the refocused approach opens room to manoeuvre but does not yet prove the next steps will pay off.
Should investors sell immediately? Or is it worth buying Thyssenkrupp?
The Bear Case: Certainty in Law, Difficulty in Practice
The serious counterargument is that planning certainty can coexist with a hard commercial slog. If hydrogen cannot be sourced on workable terms, a binding funding notice will not solve that on its own. The very emphasis on economic viability cuts both ways: it can shield the company from uneconomic decisions, but it can also tie the ramp-up more tightly to the right supply conditions. A positive funding event, then, is no reason to price in a smooth path ahead.
The risk sits in the gap between legal cover and commercial deliverability. Investors should watch not just the next project headline but what it actually says. Another preparatory update carries a different weight from binding results on supply. Keeping that line clear stops procedural progress from being mistaken for economic outcome. Whether Thyssenkrupp can explain the commercial preconditions of the next stage more concretely is what will matter — not every additional statement counts as a delivery, only one that makes the link between funding framework, hydrogen availability and a viable ramp-up more robust.
A Bigger Stake, With a Caveat
The Morgan Stanley disclosure, published Friday, shows a total position of 7.96%, up from 7.46% previously. The composition matters here: the filing covers voting rights and instruments together, so the larger total is not the same as an equally large direct shareholding, and the notice alone says nothing about the bank's strategic intentions. Voting rights account for 5.28%, instruments for 2.67%. Anyone looking only at the headline total is overlooking how the position is actually built.
A Lower Fair Value, a Buy Rating Unchanged
DZ Bank had already taken a more cautious view on valuation. According to media reports, it cut its fair value for Thyssenkrupp to EUR 15 from EUR 16 on 29 October, while keeping its "Buy" rating. The move pairs a lower valuation with a still-positive recommendation — neither a downgrade of the investment verdict nor an unchanged view of fair value. Both halves belong together when weighing the analyst action. The stake disclosure and the buy call also answer different questions: one describes a reported position, the other a view on the shares, and no single verdict on the share price follows from either.
The Spinoff and the December Date
Lurking in the background is the carve-out of tk accelis completed roughly a week ago, with its listing on the Frankfurt stock exchange. Thyssenkrupp retained a 51% stake, so the step was not a full separation from the business. The next fixed point for assessing the group is the annual report for fiscal 2025/26, scheduled for publication on 8 December 2026, alongside an annual press conference and an analyst and investor conference.
Until then, the stake disclosure, the analyst verdict and the completed spinoff step each deserve to be weighted separately. None of them, on its own, offers a substantiated explanation for the recent share-price gain.
Ad
Thyssenkrupp Stock: New Analysis - 5 November
Fresh Thyssenkrupp information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
